BetterLife Pharma Inc. has emphasized the benefits of its proprietary compound BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD), in light of recent Phase 2 trial results demonstrating LSD microdosing's ineffectiveness for depression. The company notes that BETR-001 maintains its non-hallucinogenic properties even at high doses and does not develop tolerance with repeated use, permitting chronic administration while preserving therapeutic effectiveness. Dr. Ahmad Doroudian, CEO of BetterLife, explained that the capacity to administer full doses without inducing hallucinations is significant because it removes the necessity for specialized clinics and extended monitoring protocols typically associated with psychedelic treatments. "BETR-001 overcomes all these hurdles and can be administered at its full effective dose without any hallucinations," Doroudian stated.
The company is concluding IND-enabling studies and intends to submit an Investigational New Drug application and commence human clinical trials in the second half of 2026. Initial development priorities for BETR-001 encompass treatment of traumatic brain injury, cluster headaches, and migraine, with prospective applications for a wide spectrum of psychiatric disorders to be investigated as development advances. BetterLife's synthesis patent for BETR-001 eliminates regulatory obstacles, while pending composition and method-of-use patents cover treatment of various neurological disorders until approximately 2042. The compound's non-controlled status allows for potential self-administration, setting it apart from regulated psychedelics.
For additional information about the company's progress, visit https://www.blifepharma.com. BetterLife Pharma Inc. is listed on the Canadian Securities Exchange under symbol BETR, on the OTCQB under BETRF, and on the Frankfurt Stock Exchange under NPAU. The company also possesses a drug candidate for viral infections and is exploring strategic alternatives for its development.
